Atogepant, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention, led to fewer monthly migraine days in episodic monthly migraine patients, results of a phase IIb/III trial showed here.
© American Academy of Pain Medicine. All Rights Reserved | Privacy Policy | Media Resources | Powered by Insight Marketing Group
American Academy of Pain (AAMP) is a nonprofit, 501(c)(6) tax-exempt organization.